Re-appointment of Mr. Lalit Mehta as Chairman & Managing Director, Mr. Rajesh Mehta as Executive Director & Mr. Megh Mehta as Executive Director w.e.f. 01-04-2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts less than Nifty Microcap 250 and 1.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Samrat Pharmachem's board has re-appointed Mr. Lalit Mehta (88, founder-promoter) as Chairman & Managing Director, Mr. Rajesh Mehta (61, his son) as Executive Director, and Mr. Megh Mehta (32, his grandson) as Executive Director, each for a 5-year term starting April 1, 2026 to March 31, 2031. All three have been on the board since the company's incorporation (except Megh, who joined in 2015) and are not debarred by SEBI or any authority. The re-appointments are subject to shareholder approval at the upcoming 33rd AGM. Post April 2026, the board will consist of these three executive directors plus four independent directors.
This is a continuity announcement with no negative implications — existing leadership is being retained. However, all three executive seats are held by members of the same promoter family (three generations), which means the company's day-to-day management remains fully in family hands. Shareholders will need to approve these re-appointments at the AGM, but this is typically a routine exercise for promoter-driven companies.